Your browser doesn't support javascript.
loading
Plan B (-cell) in atherosclerosis.
Nus, Meritxell; Tsiantoulas, Dimitrios; Mallat, Ziad.
Afiliação
  • Nus M; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
  • Tsiantoulas D; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
  • Mallat Z; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK; Institut National de la Santé et de la Recherche Médicale, U970 Paris, France. Electronic address: zm255@medschl.cam.ac.uk.
Eur J Pharmacol ; 816: 76-81, 2017 Dec 05.
Article em En | MEDLINE | ID: mdl-28882560
Atherosclerosis is a leading cause of death worldwide. It is a complex chronic inflammatory disease involving interactions between vascular, circulating and immune cells. B cells play an important role in chronic inflammation producing antibodies and regulating T and natural killer (NKT) cell activation. The role of B cells in atherosclerosis is complex, with atherogenic and protective roles assigned for distinct B cell subsets. Drugs that deplete B cells or modulate their functions are now used in the treatment of various autoimmune diseases in humans. Here, we briefly review the roles of B cell subsets in atherogenesis, and emphasize the potential impact of B cell targeted therapies on the cardiovascular risk of treated patients. Developing more B cell subset-specific therapies would lead to more effective treatments with enhanced safety profile.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Aterosclerose Limite: Animals / Humans Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos B / Aterosclerose Limite: Animals / Humans Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2017 Tipo de documento: Article